Latest news with #Retatrutide
Yahoo
02-06-2025
- Business
- Yahoo
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
25-04-2025
- Business
- Time of India
Hot Stocks: 3 stocks that may give returns between 13-43%
A look at some of the latest stock recommendations by analysts . These stocks are expected to return between 13% and 43% as per analyst price targets . DIVI'S LABORATORIES by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Boria: The price (& size) of these hearing aids might surprise you Learn More Undo BROKERAGE: CITI Price Target: Rs 7,050 CMP: Rs 6,216 | Upside: 13% Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Orforglipron, Eli Lilly's oral diabetes drug, next addition in Divi's pipeline Potential to become primary supplier Company has announced $170-million capex, which Citi believes is primarily for GLP-1—medication to manage Type 2 diabetes and obesity Divi's could be a key player for Eli Lilly's next weight loss product—Retatrutide DEVYANI INTERNATIONAL BROKERAGE: BERNSTEIN Price Target: Rs 220 CMP: Rs 179 | Upside: 23% Reiterate positive view after acquiring majority stake in unlisted Sky Gate Hospitality, which owns Biryani By Kilo and other cloud kitchens Value accretive for Devyani as deal done at 2-2.5 times sales QSR (Quick Service Restaurant) chains at 4-6.6 times sales FY25 and FY26 earnings to be volatile because of M&A and growth moves Live Events ANANT RAJ BROKERAGE: NOMURA Price Target: Rs 700 CMP: Rs 488 | Upside: 43% Reiterate Buy rating but cut price target from Rs 750 to Rs 700 citing a more conservative stance on its data centre unit Company's 307 Mega Watt Data Centre target will be reached by FY32-33 as against earlier expectations of FY31 Valuations still attractive as earnings per share estimated to grow over 40% on a compounded basis over FY26-27
